News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Eli Lilly and Company (LLY) Faces Financial Difficulty Over Loss Of Cymbalta Patent


1/3/2014 8:34:22 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Eli Lilly is banking that new drugs will counter the massive drop in profits from losing exclusivity of its top-selling antidepressant Cymbalta. The FDA already approved six less costly versions of the drug after its patent expired Dec. 11, 2013. The patent loss is expected to take a huge bite out of the medication’s multibillion-dollar profits. The drug generated Lilly sales of $4.2 billion between January 2012 and September 2012.

Help employers find you! Check out all the jobs and post your resume.

Read at News Release

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES